Stay updated on Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The clinical trial page now displays the study record for neo-adjuvant pembrolizumab in primary stage IV ovarian cancer, with details on its design, participants, treatments, and measured outcomes.
    Difference
    46%
    Check dated 2026-11-10T18:25:09.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0. The page otherwise continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T18:22:11.000Z thumbnail image
  3. Check
    25 days ago
    Change Detected
    Summary
    A general NIH website-transition notice appears above the 403 error page. The site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T19:51:07.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T19:33:47.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page with a 403 title and basic HTML structure, replacing the expected study content. A Home link is visible, indicating the content is blocked rather than accessible.
    Difference
    0.5%
    Check dated 2026-09-29T19:30:43.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, indicating access is blocked. The content area that previously displayed the study record is replaced by an error screen.
    Difference
    18%
    Check dated 2026-09-22T22:27:27.000Z thumbnail image

Stay in the know with updates to Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.